Introduction
============

Osteoporosis is a disease that affects primarily postmenopausal women, especially those with vitamin D deficiency and a lifestyle of low physical activity. In China, the prevalence of osteoporosis has grown rapidly, the prevalence of osteoporosis in people aged 50 years and older in 2015 being more than twice the prevalence identified in 2006 (34.65% vs 15.7%, respectively). The prevalence was higher in females than in males (25.41% vs 15.33%, respectively) and increased with age.[@b1-cia-13-2367] Moreover, vitamin D deficiency is also very common in China. In our previous study,[@b2-cia-13-2367] more than 82.5% of elderly community residents had vitamin D insufficiency, and approximately 43% had vitamin D deficiency -- even during summer. Deficiency of vitamin D inevitably leads to secondary hyperparathyroidism, which augments bone resorption, compromises bone quality, and increases risk of falling and fractures.

Sclerostin is an osteocyte-secreted glycoprotein that inhibits osteoblast proliferation and differentiation, as well as promoting apoptosis by inhibiting canonical Wnt-signaling.[@b3-cia-13-2367] Sclerostin may help modulate systemic and local factors, such as calcitriol, parathyroid hormone (PTH), glucocorticoids, and tumor necrosis factor (TNF)-alpha.[@b4-cia-13-2367] We determined that serum sclerostin also positively correlates with bone mineral density (BMD), negatively correlates with serum TGF-beta, and changes with age in the postmenopausal period.[@b5-cia-13-2367] Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that regulates homeostasis of phosphate and 1,25-dihydroxyvitamin D (1,25(OH)~2~D).[@b6-cia-13-2367] As the most metabolically active form of vitamin D, 1,25(OH)~2~D plays a key role in the regulation of extracellular calcium concentration and bone metabolism. Calcitriol has been used widely to treat osteoporosis, especially in the elderly population in China. However, the effects of calcitriol on the levels of serum FGF-23 and sclerostin have not been determined; moreover, it remains unclear whether there are correlations among FGF-23, sclerostin, and calcitriol. In the current study, we assessed the effect of calcitriol on serum FGF-23 and sclerostin in postmenopausal women with low bone mass to ascertain the following: 1) whether serum FGF-23 and sclerostin significantly changed after calcitriol treatment; 2) whether these changes evoke corresponding changes in serum intact PTH (iPTH) and bone turnover; and 3) the changes in muscle mass and muscle strength during treatment.

Methods
=======

Study design and study population
---------------------------------

We carried out a randomized, double-blind controlled study. The logistics of calcitriol and placebo, along with each code for randomization, were prepared by personnel from the Department of Medicine, Qingdao Chia Tai Haier Pharmaceutical Co, Ltd, Qingdao, Shandong, China. Both investigators and participants were unaware of the codes.

All the participants were recruited from the town of Meilong in Minhang District of Shanghai, China, from November 2016 to April 2017. Totally, 320 postmenopausal women were recruited, and after excluding patients who did not give consent (58 patients), who had normal bone mass (44 patients), who had a level of serum 25(OH)~2~D that exceeded 30 ng/mL (45 patients), and who did not comply with or finish the study (32 patients), 141 participants completed the study and were included in the analysis. Based on a review of medical charts and physical examination, we selected participants in good health. All were able to walk independently. No included patient had severe disease that interfered with vitamin D metabolism, such as hyperthyroidism, hyperparathyroidism, hepatic failure, renal failure, or end-stage cancer. No included patient received medication that was likely to affect bone or vitamin D metabolism (eg, glucocorticoids, heparin, warfarin, thyroxine, sex hormones, bisphosphonates, selective estrogen-receptor modulators, calcitonin, PTH analogs, or calcitriol). This study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. Approval was obtained from the Huadong Hospital Ethics Committee, Shanghai, China (project number 2014K004).

Treatment
---------

Participants were randomized to receive either calcitriol or placebo. The calcitriol group received oral calcitriol (Qingdao Chia Tai Haier Pharmaceutical Co, Ltd) at a dosage of 0.5 µg/day for 12 weeks. All the participants were required to avoid calcium supplements and were asked to maintain their usual dietary habits during the study period. According to a survey launched in 2015 in China, the average calcium intake from the food for old persons was about 400 mg/day; so, dietary calcium intake was lacking in China.[@b7-cia-13-2367]

Anthropometry
-------------

All anthropometric measurements were made by well-trained staff. Weight and height were determined with the participants dressed in light clothing and without wearing shoes. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters (kg/m^2^).

Handgrip measurement
--------------------

Isometric handgrip was measured using a digital handgrip dynamometer (Takei Scientific Instruments, Niigata, Japan). Grip strength was measured three times per hand with the patient standing. The results were represented as the combined grip strength in kilograms, ie, the sum of the largest reading from each hand.

Laboratory analyses
-------------------

Patients underwent collection of fasting serum samples for biochemical analysis, including bone turnover markers, calciotropic hormones, FGF-23, and sclerostin. These factors were analyzed at baseline and at the end of the study. Serum samples were collected between 0700 and 0900 hours after a 10-hour fast.

Bone density measurements
-------------------------

BMD values, including those for lumbar vertebrae (L1--4), left femoral neck (FN), and total hip, were measured using dual-energy X-ray absorptiometry (DXA; Hologic Delphi A; Hologic Inc, Waltham, MA, USA). Body composition was measured by a whole body scan with the same machine operated in the slow scan mode. To minimize interobserver variations, all scans and analyses were conducted by the same investigator. The day-to-day coefficients of variance (CVs) of these observations were 0.86% in the lumbar spine BMD, 1.86% in the femur BMD, 0.95% in the total hip BMD, and 0.74% in lean mass. The densitometer was standardized using a standard phantom prior to each measurement.

Analysis of serum FGF-23 and sclerostin levels
----------------------------------------------

Commercially available ELISA kits for FGF-23 (Kainos Laboratories Inc, Tokyo, Japan; intraassay and interassay CV, \<2.8% and \<3.8%, respectively) and sclerostin (R&D Systems, Minneapolis, MN, USA; intraassay and interassay CV, \<2.1% and \<10.8%, respectively) were applied for measurement of serum FGF-23 and sclerostin.

Bone turnover markers
---------------------

Serum osteocalcin (bone Gla protein \[BGP\]; Hoffman-La Roche Ltd., Basel, Switzerland) and serum cross-linked C-terminal telopeptide of type I collagen (CTX; Roche) were used as bone turnover markers. The within-run and between-run intra-assay CV was \<7% for osteocalcin and \<6% for CTX.

Calciotropic hormone measurements
---------------------------------

Serum iPTH and 25(OH)~2~D were measured by electro-chemiluminescence (Roche). The within-run intra-assay CV was \<3.4%, and the between-run intra-assay CV was \<7%.

Statistical analyses
--------------------

Data were represented as mean±SD, mean (95% CI), and median (IQR) as appropriate. Variables were compared with the independent-samples Student's *t*-test if normally distributed or with the Mann--Whitney *U* test if the distribution was skewed. Paired Student's *t*-test and Wilcoxon signed-rank test were used for within-group comparisons before and after treatment. Pearson or Spearman correlation coefficients were determined to assess associations of serum sclerostin or FGF-23 with bone turnover markers, calciotropic hormones, and biochemical markers. Absolute changes in plasma FGF-23, sclerostin, iPTH, 25(OH)~2~D, calcium, phosphorus, ALP, uric acid, creatinine, bone turnover markers, 24-hour urinary calcium concentrations, and handgrip strengths from baseline to Week 12 were ascertained in the calcitriol treatment group. These parameters were stratified by the direction of the change from baseline to Week 12: decrease (Week 12 -- baseline ≤0) or increase (Week 12 -- baseline \>0). Logistic regression modeling was performed to estimate the association of the decrease/increase in each analyte with the decrease/increase in sclerostin or FGF-23. All analyses were performed using SPSS 16.0 (IBM Corporation, Armonk, NY, USA). Two-tailed *P*-values \<0.05 were considered statistically significant.

Results
=======

Demographic information and baseline characteristics of the study subjects are shown in [Table 1](#t1-cia-13-2367){ref-type="table"}. There was no statistically significant difference for all the characteristics between the two groups. The BMD values of all participants were indicative of osteopenia or osteoporosis. Appendicular skeletal muscle mass index (ASMI = appendicular skeletal muscle mass/height^2^) was 6.23±0.73 kg/m^2^ or 5.95±0.69 kg/m^2^, respectively, which showed that these postmenopausal women did not suffer from sarcopenia according to the cut point value of our previous study.[@b8-cia-13-2367] Blood levels of iPTH were 44.78±15.5 pg/mL and 47.0±21.1 pg/mL, respectively, and those of 25(OH)~2~D were 17.10±7.8 ng/mL and 15.8±9.6 ng/mL, respectively. Blood levels of sclerostin were 103.4±28.0 pg/mL and 120.55±52.6 pg/mL, respectively, and for FGF-23, the levels were 101.7±46.0 ng/mL and 118.79±24.7 ng/mL, respectively, which did not show any significant difference between the two groups ([Table 1](#t1-cia-13-2367){ref-type="table"}).

In the calcitriol treatment group, serum iPTH, sclerostin, ALP, serum creatinine, uric acid, serum glucose, and 24-hour urinary calcium levels were found to be significantly changed posttreatment ([Table 1](#t1-cia-13-2367){ref-type="table"}). No significant change in serum levels of 25(OH)~2~D, FGF-23, calcium, or phosphorus were noted. Left handgrip strength increased significantly by 3.7% (*P*=0.019), but right handgrip strength did not change significantly. However, in the placebo group, there was no significant change for all the parameters between pretreatment and posttreatment values ([Table 2](#t2-cia-13-2367){ref-type="table"}). Treatment with calcitriol for 12 weeks resulted in a significant increase in serum uric acid and creatinine, but all of these parameters remained within the normal range from the pretreatment to the posttreatment periods ([Table 2](#t2-cia-13-2367){ref-type="table"}).

As for the difference between the calcitriol and placebo groups after 12-week treatment, significant decreases in serum iPTH (mean change: −8.08 pg/mL, 95% CI: −10.55 to −5.38 pg/mL; *P*=0.035) and sclerostin (mean change: −7.05 pg/mL, 95% CI: −19.8 to −2.75 pg/mL; *P*=0.039), as well as significant increases in serum creatinine (mean change: 2.00 mmol/L, 95% CI: 1.08 to 5.09 mmol/L; *P*=0.027), uric acid (mean change: 7.89 mmol/L, 95% CI: 2.2 to 13.99 mmol/L; *P*=0.032), 24-hour urinary calcium (mean change: 2.78 mmol, 95% CI: 1.10 to 3.05 mmol; *P*=0.0026), and left handgrip strength (mean change: 2.12 kg, 95% CI: 1.87 to 2.36 kg; *P*=0.03) were observed, compared to the placebo group ([Table 2](#t2-cia-13-2367){ref-type="table"}).

Results of pretreatment and posttreatment correlation analyses of sclerostin and FGF-23 with bone metabolic markers and other parameters of calcitriol treatment group are summarized in [Table 3](#t3-cia-13-2367){ref-type="table"}. At baseline, sclerostin and FGF-23 were not correlated with 25(OH)~2~D, iPTH, bone turnover markers, or other parameters. In contrast, posttreatment serum sclerostin level was weakly but significantly positively correlated with iPTH level (*r*=0.277; *P*=0.01) and negatively correlated with left handgrip strength (*r*=−0.338; *P*=0.03) and 24-hour urinary calcium level (*r*=−0.221; *P*=0.04). Posttreatment serum FGF-23 level was negatively correlated with CTX (*r*=−0.326; *P*=0.02) and 24-hour urinary calcium (*r*=−0.356; *P*=0.01) levels ([Table 3](#t3-cia-13-2367){ref-type="table"}). We noted that urinary calcium was also negatively correlated with posttreatment iPTH level (*r*=−0.335; *P*=0.001); we further determined that, after adjusting for urinary calcium level, serum sclerostin was still positively correlated with iPTH (*r*=0.218; *P*=0.043) and negatively correlated with left handgrip strength (*r*=−0.317; *P*=0.041).

Factors associated with a decrease in the serum sclerostin or FGF-23 level of the calcitriol treatment group are presented in [Table 4](#t4-cia-13-2367){ref-type="table"}. We constructed a multivariate logistic regression model to examine the relationship between any change in the parameters and the desired end point of a significant decrease in serum sclerostin level. We found that a decrease in serum iPTH was associated with a significant decrease in serum sclerostin after treatment with calcitriol (OR, 7.90; 95% CI, 2.28--27.42; *P*=0.002; [Table 4](#t4-cia-13-2367){ref-type="table"}).

Discussion
==========

Both sclerostin and FGF-23 are produced in osteocytes, and they function as crucial calcium regulators in bone mineralization balance. Sclerostin and FGF-23 are known to inhibit bone formation, with several cross-sectional studies having identified inverse associations of serum FGF-23[@b9-cia-13-2367] and sclerostin[@b10-cia-13-2367] with numerous biochemical markers of bone turnover. In this study, we found that calcitriol treatment yielded significant decreases in serum iPTH and sclerostin, as well as significant increases in serum creatinine, uric acid, and left handgrip strength. Thus, serum sclerostin was negatively regulated by calcitriol, and the change of sclerostin positively correlated with the change of iPTH.

Several studies have addressed the putative regulation of vitamin D by sclerostin, but no study has identified the reason and mechanism for this phenomenon. Sandal et al[@b11-cia-13-2367] found that pregnant women with vitamin D deficiency had circulating sclerostin levels that were similar to those who were vitamin D sufficient. In a study that included 279 men and women, calcium and vitamin D supplementation at a dosage of 700 IU/day for 2 years increased serum sclerostin levels in men (13.1% increase; *P*\<0.01 vs placebo) but did not change sclerostin levels significantly in women.[@b12-cia-13-2367] Sankaralingam et al[@b13-cia-13-2367] reported that intramuscular injection of a 300,000 IU bolus of vitamin D significantly increased the concentration of serum sclerostin. Acibucu et al[@b14-cia-13-2367] evaluated a group of 44 patients with vitamin D deficiency who had a significant decrease (−19.4%; *P*\<0.01) in sclerostin levels after being treated with monthly intramuscular injection of 300,000 IU of vitamin D (cholecalciferol). Cidem et al[@b15-cia-13-2367] demonstrated that treatment of vitamin D--deficient patients with calcium at a dosage of 1,200 mg/day for 2 months and vitamin D3 at a dosage of 300,000 IU/week for 1 month produced significantly increased serum 25(OH)~2~D and significantly decreased serum sclerostin in these patients. In this study, we found that treatment using calcitriol 0.5 µg/day without calcium in postmenopausal women for only 12 weeks significantly increased muscle strength and depressed serum level of iPTH and sclerostin.

Active vitamin D can augment muscle strength and improve lower limb balance. The results of multiple studies have shown that postmenopausal women who take active vitamin D have increased muscle power, show a longer walking distance, and are more likely to have a normal PTH levels than are postmenopausal women who do not take active vitamin D.[@b16-cia-13-2367],[@b17-cia-13-2367] However, the beneficial effects of active vitamin D on muscle strength may be more pronounced when the muscle is weaker at baseline. This could explain why, in our study, treatment with calcitriol for 12 weeks, which was relatively short, only yielded a significant increase in handgrip strength on the left side, which is typically nondominant.

Sclerostin appears to be a fundamental regulator of bone mass. However, the factors determining the absolute level of sclerostin expression have not been established fully. Known regulators of sclerostin include mechanical loading (exercise)[@b18-cia-13-2367] and PTH.[@b19-cia-13-2367] Sclerostin also has been shown to be regulated by catabolic stimuli, such as TNF and TNF-related weak-inducer of apoptosis (TWEAK).[@b20-cia-13-2367] Several lines of evidence have indicated that circulating sclerostin levels can be inhibited by treatment with PTH or by implementation of an exercise program. Routine exercise and continuous exposure to gravity are likely to be important factors in sclerostin regulation. In elderly individuals, increased muscle strength might increase mechanical loading of bone, which has been shown to inhibit sclerostin expression by osteocytes.[@b19-cia-13-2367] Therefore, we speculate that in our study, increased muscle strength acts on bone to inhibit sclerostin expression after calcitriol treatment. These findings suggest that therapies targeting muscle in the setting of disuse atrophy may potentially attenuate bone loss and promote bone strength, the results being similar to those of a previous study.[@b21-cia-13-2367]

In our study, we demonstrated that serum creatinine and uric acid were significantly increased by calcitriol treatment. In the human body, serum creatinine originates from creatine, of which approximately 95% is stored in the skeletal muscle.[@b22-cia-13-2367] In a clinical study, Baxmann et al[@b23-cia-13-2367] found that serum and urinary creatinine correlated significantly with body weight and with lean (fat-free) mass. Huh et al[@b24-cia-13-2367] also determined that serum creatinine correlated positively with total skeletal muscle mass and appendicular skeletal muscle mass, as well as being correlated negatively with body fat percentage. Because the amount of creatinine per unit of skeletal muscle mass and the breakdown rate of creatine are consistent metrics, it was suggested that concentration of plasma creatinine is a stable, direct reflection of skeletal muscle mass.[@b25-cia-13-2367] Uric acid is another marker of muscle function. The findings of many studies have suggested that uric acid might play a protective role in the decline in muscle strength that occurs with aging. High levels of uric acid might counteract the excessive production of free radicals that damage muscle proteins and diminish muscle mass and strength.[@b26-cia-13-2367] Macchi et al[@b26-cia-13-2367] demonstrated that uric acid could have favorable effects on skeletal muscle strength in patients who are older. Molino-Lova et al[@b27-cia-13-2367] showed that high levels of uric acid in serum were independently associated with better muscle function and that uric acid had a favorable effect on progression of sarcopenia among individuals in the oldest age group. Thus, muscle strength and volume correlate with the level of serum creatinine and uric acid in their physiologic range.

However, the effects of calcitriol on serum creatinine and uric acid have not been addressed sufficiently in the literature. In the current study, all the patients were healthy postmenopausal women who maintained their typical dietary habits and lifestyle and were monitored for only 12 weeks. Patients in this study had serum levels of creatinine and uric acid in the normal range pretreatment and posttreatment. Therefore, we speculate that the observed increases in serum creatinine and uric acid after calcitriol treatment can be attributed to improvements in muscle metabolism. So, we cannot rule out the possibility that the increased muscle strength caused by calcitriol treatment modulated the serum levels of sclerostin, creatinine, and uric acid.

Conclusion
==========

Our results show that circulating concentrations of sclerostin and iPTH were decreased and serum creatinine, uric acid, and muscle strength were enhanced in response to treatment with calcitriol for 12 weeks. A significant correlation was seen among serum sclerostin, serum iPTH, and muscle strength posttreatment. These findings raise the possibility that calcitriol may mediate the levels of iPTH and skeletal anabolic metabolism, which, in turn, further suppresses the production of sclerostin. More research is warranted to dissect this putative physiologic mechanism.
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###### 

Baseline characteristics of study subjects

  Parameter                  Calcitriol-treatment (mean±SD)   Placebo (mean±SD)     *P*-value
  -------------------------- -------------------------------- --------------------- -----------
                                                                                    
  Age, years                 58.2±8.1                         57.1±8.2              0.65
  Height, m                  154.6±5.2                        156.2±6.1             0.27
  Weight, kg                 64.5±6.2                         66.4±7.8              0.07
  BMI, kg/m^2^               24.3±3.1                         23.5±3.2              0.52
  BMD, g/cm^2^ (L1--4)       0.788±0.10                       0.813±0.28            0.66
  BMD, g/cm^2^ (FN)          0.636±0.08                       0.645±0.13            0.64
  BMD, g/cm^2^ (total hip)   0.786±0.10                       0.719±0.10            0.49
  ASMI, kg/m^2^              6.18±0.73                        5.95±0.69             0.07
  FGF-23, pg/mL              101.7±46.0                       120.55±52.6           0.31
  SOST, pg/mL                103.4±28.0                       118.79±24.7           0.29
  PTH, pg/mL                 44.78±15.5                       47.0±21.1             0.08
  25(OH)~2~D, ng/mL          17.10±7.8                        15.8±9.6              0.22
  CTX, pg/mL                 416.2±125.8                      393.26±132.1          0.47
  BGP, ng/mL                 18.7±4.8                         20.3±7.1              0.30
  ALP, IU/L                  82.9±20.7                        78.6±22.9             0.32
  Blood glucose, mmol/L      6.02±1.0                         5.8±1.2               0.29
  UA, mmol/L                 291.3±56.4                       314.5±76.3            0.19
  TC, mmol/L                 5.6±0.8                          5.2±0.9               0.054
  TG, mmol/L                 1.5±0.6                          2.3±1.7               0.066
  Serum Ca, mmol/L           2.44±0.08                        2.37±0.19             0.32
  Serum P, mmol/L            1.30±0.13                        1.18±0.17             0.28
  Urinary Ca, mmol           4.32±1.8                         4.58±2.3              0.15
  Serum Cr, mmol/L           60.3±9.3                         64.5±11.6             0.61
  GFR, mL/kg⋅s               110.2±23.5                       115±22.7              0.53
  Grip (left), kg            19.95 (17.75--22.0)              19.57 (17.0--22.0)    0.31
  Grip (right), kg           21.70 (18.0--25.0)               21.86 (18.0--25.25)   0.66

**Note:** Data are presented as mean±SD or median (25th--75th percentile).

**Abbreviations:** 25(OH)~2~D, serum 1,25-dihydroxyvitamin D; ASMI, appendicular skeletal mass index; BGP, bone Gla protein or osteocalcin; BMD, bone mineral density; BMD (L1--4), BMD of lumbar vertebrae 1--4; BMD (FN), BMD of femur neck; BMD (total hip), BMD of total hip; BMI, body mass index; Cr, creatinine; CTX, cross-linked C-terminal telopeptide of type I collagen; FGF-23, fibroblast growth factor-23; GFR, glomerular filtration rate; Grip (left), grip strength of left hand; Grip (right), grip strength of right hand; PTH, parathyroid hormone; SOST, sclerostin; TC, total cholesterol; TG, triglyceride; UA, uric acid; Urinary Ca, 24-hour urinary calcium.

###### 

Changes in biochemical parameters and markers of bone turnover between baseline and 12 weeks

                              Placebo (n=66)             Calcitriol (n=75)   Between-group difference (compared to placebo group)                                        
  --------------------------- -------------------------- ------------------- ------------------------------------------------------ --------- -------------------------- -------
                                                                                                                                                                         
  BMI                         −0.30 (−1.46 to 0.87)      0.61                0.32 (−0.88 to 1.52)                                   0.60      1.84 (−0.65 to 3.23)       0.33
  Grip strength (left), kg    −0.871 (−0.425 to 0.666)   0.384               2.96 (1.29 to 3.04)                                    0.019     2.12 (1.87 to 2.36)        0.03
  Grip strength (right), kg   −0.255 (−0.13 to 0.328)    0.799               1.953 (−0.044 to 2.025)                                0.051     1.81 (−0.71 to 1.99)       0.070
  ASMI, kg/m^2^               0.02 (−0.22 to 0.26)       0.86                −0.06 (−13.28 to 37.89)                                0.62      0.56 (−0.27 to 0.84)       0.23
  FGF-23, pg/mL               −5.92 (−1.99 to 13.83)     0.14                −6.77 (−27.3 to 13.79)                                 0.51      −8.36 (−12.21 to 25.77)    0.65
  SOST, pg/mL                 0.19 (−0.42 to 0.81)       0.53                −5.91 (−22.0 to −3.75)                                 0\. 016   −7.05 (−19.8 to −2.75)     0.039
  PTH, pg/mL                  5.49 (−5.01 to 15.99)      0.29                −7.79 (−11.13 to −4.44)                                0.000     −8.08 (−10.55 to −5.38)    0.035
  25(OH)~2~D, ng/mL           0.10 (−3.16 to 3.36)       0.95                −1.89 (−3.17 to 0.60)                                  0.25      5.25 (−2.37 to 8.14)       0.68
  CTX, pg/mL                  −18.39 (−98.56 to 61.77)   0.64                18.31 (−14.82 to 51.44)                                0.27      −19.98 (−95.05 to 55.04)   0.596
  BGP, ng/mL                  3.74 (−0.37 to 7.87)       0.07                −0.47 (0.27 to −1.25)                                  0.21      −1.94 (−4.38 to 0.50)      0.117
  ALP, IU/L                   −4.27 (−5.24 to 1.29)      0.21                −7.03 (−10.25 to −3.81)                                0.03      −5.17 (−12.87 to 2.54)     0.45
  Blood glucose, mmol/L       0.05 (−0.85 to 0.94)       0.09                −0.35 (−0.53 to −0.17)                                 0.045     0.01 (−0.61 to 0.87)       0.727
  UA, mmol/L                  −27.98 (−81.5 to 25.53)    0.29                20.23 (8.91 to 31.53)                                  0.001     7.89 (2.2 to 13.99)        0.032
  Serum Cr, mmol/L            2.03 (−4.07 to 8.12)       0.59                3.92 (2.41 to 5.42)                                    0.000     2.00 (1.08 to 5.09)        0.027
  TC, mmol/L                  4.85 (−6.87 to 16.57)      0.38                0.10 (−0.09 to 0.30)                                   0.298     −0.40 (−0.89 to 0.08)      0.101
  TG, mmol/L                  17.27 (−20.39 to 54.95)    0.33                −0.19 (−0.33 to 0.05)                                  0.07      0.48 (−0.02 to 0.94)       0.061
  Serum Ca, mmol/L            −0.04 (−0.08 to 0.015)     0.16                0.02 (−0.003 to 0.04)                                  0.09      −0.03 (−0.65 to 0.01)      0.064
  Serum P, mmol/L             0.91 (−0.93 to 2.75)       0.32                0.05 (−0.01 to 0.08)                                   0.11      −0.08 (−0.14 to 0.02)      0.36
  Urinary Ca, mmol            1.92 (−1.99 to 13.83)      0.15                1.51 (0.83 to 2.19)                                    0.000     2.78 (1.10 to 3.05)        0.026

**Note:** Data are presented as mean change and 95% CI.

**Abbreviations:** 25(OH)~2~D, serum 1,25-dihydroxyvitamin D; ASMI, appendicular skeletal mass index; BGP, bone Gla protein or osteocalcin; BMD, bone mineral density; BMD (L1--4), BMD of lumbar vertebrae 1--4; BMD (FN), BMD of femur neck; BMD (total hip), BMD of total hip; BMI, body mass index; Cr, creatinine; CTX, cross-linked C-terminal telopeptide of type I collagen; FGF-23, fibroblast growth factor-23; GFR, glomerular filtration rate; Grip (left), grip strength of left hand; Grip (right), grip strength of right hand; PTH, parathyroid hormone; SOST, sclerostin; TC, total cholesterol; TG, triglyceride; UA, uric acid; Urinary Ca, 24-hour urinary calcium.

###### 

Correlation analyses between sclerostin, FGF-23, and other parameters before and after treatment in the calcitriol group

                      PTH               25(OH)~2~D     CTX                 ALP            Cr             UA             Serum Ca       Serum P        Urinary Ca          Grip strength (left)   Grip strength (right)   SOST          FGF-23
  ------------------- ----------------- -------------- ------------------- -------------- -------------- -------------- -------------- -------------- ------------------- ---------------------- ----------------------- ------------- -------------
  **Pretreatment**                                                                                                                                                                                                                     
  SOST                0.138^0.20^       0.102^0.34^    −0.080^0.46^        −0.134^0.21^   0.047^0.67^    0.020^0.85^    0.005^0.96^    −0.003^0.98^   −0.143^0.18^        0.093^0.55^            −0.071^0.65^            1             0.090^0.41^
  FGF-23              0.177^0.10^       0.091^0.40^    −0.182^0.09^        −0.118^0.28^   0.083^0.44^    0.232^0.03^    −0.048^0.66^   0.012^0.91^    0.013^0.91^         0.057^0.71^            0.048^0.76^             0.090^0.41^   1
  **Posttreatment**                                                                                                                                                                                                                    
  SOST                **0.277^0.01^**   −0.057^0.60^   0.069^0.53^         −0.131^0.22^   −0.006^0.96^   −0.104^0.33^   −0.096^0.37^   −0.067^0.54^   −**0.2210^0.04^**   −**0.3380^0.03^**      −0.291^0.06^            1             0.045^0.68^
  FGF-23              0.015^0.89^       −0.128^0.24^   −**0.3260^0.02^**   0.082^0.45^    0.018^0.87^    0.109^0.31^    0.027^0.80^    0.165^0.12^    −**0.3560^0.01^**   −0.036^0.82^           −0.111^0.47^            0.045^0.68^   1

**Note:** Bold figures indicate statistically significant.

**Abbreviations:** 25(OH)~2~D, serum 1,25-dihydroxyvitamin D; Ca, serum calcium; Cr, creatinine; CTX, cross-linked C-terminal telopeptide of type I collagen; FGF-23, fibroblast growth factor-23; Grip (left), grip strength of left hand; Grip (right), grip strength of right hand; PTH, parathyroid hormone; SOST, sclerostin; UA, uric acid; Urinary Ca, 24-hour urinary calcium.

###### 

Results of multiple regression for the decrease in sclerostin or FGF-23 posttreatment in the calcitriol group

                                     PTH                  UA      Cr      ALP    Urinary Ca   Grip strength (left)
  ---------------------------------- -------------------- ------- ------- ------ ------------ ----------------------
                                                                                              
  **SOST**                                                                                    
  B                                  2.07                 1.75    1.18    1.83   0.96         0.54
  OR (95% CI) for decrease in SOST   7.90 (2.28--27.42)                                       
  *P*-value                          0.001                0.13    0.17    0.17   0.33         0.46
                                                                                              
  **FGF-23**                                                                                  
  B                                  −0.03                −0.13   −0.35   0.13   −5.16        0.13
  *P*-value                          0.76                 0.24    0.37    0.21   0.67         0.20

**Notes:** Decreases in FGF-23 are defined as having change from baseline ≤0. Decreases in SOST are defined as having change from baseline ≤0.

**Abbreviations:** Cr, creatinine; FGF-23, fibroblast growth factor-23; Grip (left), grip strength of left hand; PTH, parathyroid hormone; SOST, sclerostin; UA, serum uric acid; Urinary Ca, 24-hour urinary calcium.
